https://orcid.org/0000-0001-9681-0515
References
- Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–1821.
- Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol. 2012;3(4):209–225.
- Antman GG, Berliner O, Erlich R, et al. Uveitis induced by brentuximab vedotin-A novel adverse response to antibody-drug conjugate therapy. Case Report, Clin Oncol Case Rep. 2020;3(3). https://www.scitechnol.com/peer-review/uveitis-induced-by-brentuximab-vedotina-novel-adverse-response-to-antibodydrug-conjugate-therapy-Ar7u.php?article_id=10946
- Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
- Carson KR, Newsome SD, Kim EJ, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the southern network on adverse reactions (SONAR) project. Cancer. 2014;120(16):2464–2471.
- Bhatti MT, Salama AKS. Neuro-ophthalmic side effects of molecularly targeted cancer drugs. Eye. 2018;32(2):287–301.
- Cunningham ET, Moorthy RS, Zierhut M. Immune checkpoint inhibitor-induced uveitis. Ocul Immunol Inflamm. 2020;28(6):847–849.
- Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo clinic experience. British J Ophthalmol. 2021;105(9):1263–1271.
- Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes. Ocul Immunol Inflamm. 2021;29(1):203–211.
- Lee RW, Nicholson LB, Sen HN, et al. Autoimmune and autoinflammatory mechanisms in uveitis. Semin Immunopathol. 2014;36(5):581–594.
- Ke Y, Jiang G, Sun D, et al. Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis. Invest Ophthalmol Vis Sci. 2008;49(9):3999–4007.
- Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 2009;647:174–185.
- Heiser RA, Grogan BM, Manlove LS, et al. Abstract 1789: CD30+ T regulatory cells, but not CD30+ CD8 T cells, are impaired following brentuximab vedotin treatment in vitro and in vivo. Cancer Research. 2018;78(13 Supplement):1789–1789.
- Caspi RR. Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol. 2002;21(2–3):197–208.
- Pellegrini P, Berghella AM, Contasta I, et al. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol. 2003;12(1):49–61.